Hand therapy or not following collagenase treatment for Dupuytren's contracture? Protocol for a randomised controlled trial by Aglen, T. et al.
STUDY PROTOCOL Open Access
Hand therapy or not following collagenase
treatment for Dupuytren’s contracture?
Protocol for a randomised controlled trial
Terese Aglen1* , Karin Hoegh Matre1, Cecilie Lind2, Ruud W. Selles3, Jörg Aßmus4 and Tina Taule1
Abstract
Background: Dupuytren’s contracture (DC) is a fibrotic hand condition in which one or more fingers develop
progressive flexion deformities. Quality of life is diminished due to disabling limitations in performing everyday
activities. For DC patients treated with collagenase, referral for subsequent hand therapy is inconsistent. It is
unknown whether subsequent hand therapy is beneficial compared to no therapy. The purpose of this study is to
determine whether hand therapy improves DC patients’ performance of and satisfaction with performing everyday
activities one year after collagenase treatment.
Methods: We will conduct a randomised controlled trial with two treatment groups (hand therapy vs. control) of
DC patients who have received collagenase treatment. DC patients with contracted metacarpophalangeal joint(s)
(MCPJ) (hand therapy, n = 40; control, n = 40) and those with proximal interphalangeal joint(s) (PIPJ) involvement
(hand therapy, n = 40; control, n = 40) comprise two subgroups, and we will study if the treatment effect will be
different between both groups (n = 160). Patients with a previous injury or treatment for DC in the treatment finger
are excluded. Hand therapy includes oedema and scar management, splinting, movement exercises, and practice of
everyday activities. The main outcome variable is patients’ performance of and satisfaction with performing
everyday activities, as assessed with the Canadian Occupational Performance Measure. Secondary outcomes are DC-
specific activity problems, as assessed with the Unité Rhumatologique des Affections de la Main scale, and active/
passive flexion/extension of treated joints and grip force using standard measuring tools, and self-reported pain
level. Demographic and clinical variables, degree of scarring, cold hypersensitivity, number of occupational sick-
leave days are collected. Self-reported global impression of change will be used to assess patient satisfaction with
change in hand function. Assessments are done pre-injection and 6 weeks, 4 months, and 1 year later. Standard
univariate and multivariate statistical analyses will be used to evaluate group differences.
Discussion: This study aims to assess whether hand therapy is beneficial for activity-related, biomechanical, and
clinical outcomes in DC patients after collagenase treatment. The results will provide an objective basis for
determining whether hand therapy should be conducted after collagenase treatment.
Trial registration: This study has been registered at ClinicalTrials.gov as NCT03580213 (April 5, 2018).
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Background
Dupuytren’s contracture (DC), also known as
Dupuytren’s disease, is a progressive fibroprolifera-
tive disorder affecting the palmar and digital fascia
of the hand [1]. The development of nodules and
cords in the palm may lead to flexion deformity and
limitation of function [2, 3]. DC is autosomal domin-
ant with variable penetrance. Prevalence estimates
depend on geographic location, mail gender and in-
crease with age [1]. In Sweden 56% of the diagnosed
DC patients received treatment [4]. DC affects both
performance of everyday activities and quality of life
[5, 6]. The most disabling self-reported limitations in
activity include difficulties in body washing and
grooming, putting on gloves, shaking hands, and
doing carpentry [6, 7].
Currently only symptomatic treatment exists for DC
patients [8]. The only nonsurgical treatment approved
in Europe is direct injection of collagenase clostrid-
ium histolytic (CCH) into a pathological cord [9].
CCH enzymatically dissolves collagen, allowing the
contracted cords to be disrupted and eased by gentle
force 1–2 days after injection [10]. CCH is an effective
and safe treatment for DC, as shown in a five-year
follow-up study [11]. CCH is considered to be suc-
cessful when a treated joint can be extended to 0–5°
of full extension and clinical improvement exceeds
50% reduction of the contracture [12]. Patients
treated in our clinic with CCH for DC are treated
with one injection in one to three fingers. If the skin
is tight during the extension procedure two days later,
a few also get a needle fasciotomy performed in the
same procedure. It is up to the surgeon if the patient
is referred for hand therapy or not within 1–2 weeks.
Inflammatory responses resulting from collagenases’
mechanism of action are reported, in addition to some
complications; oedema, local contusions, scarring,
haematoma, persistent joint contracture, pain, poor finger
flexion, reduced grip strength, skin lesions, and tendon
lesions [2, 13–17]. Patient satisfaction deteriorates with
time if the contracture recurs [18, 19].
DC patients’ positive view of hand function after
treatment is based on self-evaluation of whether their
previous activity limitations have diminished [20]. It seems
reasonable to hypothesize that hand therapy after CCH
treatment might help to improve performance of these
activities and temper other DC-related issues.
Hand therapy plays an important role in helping
patients regain maximum function and minimizes further
disability [13]. It is a symptom-based and clinically
reasoned treatment that depends on an individual pa-
tient’s outcomes and circumstances [21, 22]. Recommen-
dations for hand therapy after treatment for DC vary in
the literature and in practice. Patient education, oedema
management [23–25], wound care and scar management
[26–28], splinting, exercises, passive stretching, and
graded return to everyday activities are mentioned [13].
To our knowledge, the only study evaluating a post-
CCH hand therapy protocol alone, relates to patients
having a severely contracted proximal interphalangeal
joint (PIPJ) [29]. In this case, hand function improved
after 4 weeks of hand therapy following CCH treatment.
However, lacking a control group, this protocol needs
further evaluation, especially using long-term follow-up.
In two other studies mentioning post-CCH treatment,
DC patients wore a night splint, and in one study, pa-
tients also performed exercises [12, 30].
The primary goal of splinting for DC is to reduce the risk
of recurrence and to prevent flexion contracture caused by
scarring [31]. If the CCH treatment is unsuccessful, a splint
might promote more joint extension [32, 33]. Targeted
splinting for PIPJ contracture has produced good results
after 4 weeks of splinting [29]. However, four systematic re-
views all conclude that evidence in the literature does not
support night splinting for DC post-surgery [21, 31, 34, 35].
It is clear from these studies, however, that compliance is
important. No definitive conclusions can be made about
the possibility that hand splinting might be beneficial post
CCH. Reasons why patients discontinued using the splint-
ing are many [22]. Optimal moulding of the splint, and the
principle of applying low-grade force for longer periods of
time, must be followed to produce tissue change without
tissue micro-tears if the purpose of the splint is to
straighten the joint further [32, 33].
With DC, ligaments and associated tissues have been
in a shortened position for a period of time. To recover
ROM, the patient’s finger ligaments and associated tis-
sues needs to be elongated through finger exercise, use
of the hand, and splinting. Exercises that maintain the
metacarpophalangeal joint (MCPJ) in flexion, and at the
same time, allow the PIPJ to be actively extended will
improve PIPJ extension. In order to lengthen an oblique
retinacular ligament that is frequently in a contracted or
shortened condition, the PIPJ can be held in full exten-
sion, and the distal interphalangeal joint (DIPJ) can be
exercised through active movement [32]. General hand
exercises are necessary if the fingers have reduced func-
tion, as will general use of the hand in everyday
activities.
In our literature search, no studies emerged that
looked at the use of activities to improve function fol-
lowing CCH treatment. In a RCT on hand injury re-
habilitation, patients with a hand injury improved more
after an occupation-based intervention combined with
exercises than when they performed exercises only [36].
Patients in the intervention group incorporated specific
activities into their daily lives. Performing meaningful
occupation-related tasks instead of rote exercises is
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critical for the efficacy of constraint-induced therapy fol-
lowing median and ulnar nerve injuries [37]. Overall
hand function improved more when patients performed
purposeful activities that mimicked typical everyday ac-
tivities than when they performed exercises alone [38].
Performing purposeful activities accelerates the recovery
of hand injuries, it also naturally increases the number
of activity repetitions compared to engaging in non-pur-
poseful activities [36]. Encouraging patients to use their
affected hand more and more in everyday activities will
also probably improve their actual performance of these
activities and satisfaction with them.
In summary, no studies have compared the effects
of hand therapy versus no therapy. Information about
the effect of hand therapy post CCH is limited. As
with other treatments, the body reacts to CCH treat-
ment by invoking a healing process. Also, patients
seek to improve activity performance. In this study
we want to investigate if hand therapy amplify the
healing process to prevent re-contracture and improve
the patients’ performance of and satisfaction with
everyday activities.
Methods/design
Aims
The main purpose of this study is to determine whether
hand therapy administered following CCH treatment for
DC improves patients’ performance of and satisfaction
with performance of their everyday activities 1 year after
CCH treatment. The comparison group will not receive
hand therapy following CCH treatment for DC. In
addition, this intervention will be evaluated in cases in-
volving PIPJ contractions versus cases involving only
MCPJ contractions.
Hypotheses
 H1. After CCH treatment for DC, patients who
receive hand therapy will improve their performance
of everyday activities more than those patients who
do not receive hand therapy.
 H2. After CCH treatment for DC, patients who
receive hand therapy will be more satisfied with
their performance of everyday activities than those
patients who do not receive hand therapy.
 H3. Involvement of the PIPJ in the DC is a better
predictor for improvement after receiving hand
therapy than involvement of only the MCPJ.
 H4. The treatment effect (hand therapy vs. control)
for the COPM will be greater for patients where
PIPJ is involved than for that where MCPJ solely is
involved
Design
The possible benefits of hand therapy on the partici-
pants’ performance and satisfaction with performing
their everyday activities will be investigated in addition
to range of motion. A randomised controlled trial with
two groups will be used (Fig. 1). One group will receive
hand therapy after CCH treatment, and the other group
will not. Participants will be randomly allocated into the
two groups. Additionally, the two groups each have two
equally sized subgroups: one with PIPJ involvement
(MCPJ and PIPJ or PIPJ only), and the other with only
MCPJ involvement. Thus, there will be four groups,
(“MCPJ and PIPJ or PIPJ only” / “MCPJ only”) x group
type (hand therapy/control) (Fig. 1). Differences on ac-
tual performance of activities and satisfaction with that
performance, before and after hand therapy or not, will
be evaluated among the four subgroups.
Setting of the study
The Department of Occupational Therapy, Orthopaedic
Clinic, Haukeland University Hospital (HUH) will oversee
the study and will be ultimately responsible for conducting
the study and results. Some participants may live far away
from the treatment location, as the HUH serves a large
geographical area around Bergen. The intervention will be
carried out in an outpatient clinic at the hospital.
Participants
This study is currently recruiting participants (study
start date: 10th of April 2018). Adult men and women
who have had their DC treated with one CCH injection
in one-tree fingers with joints summarised to ≥30° ex-
tension deficit are eligible. Patients can participate only
once. Reasons for exclusion are as follows:
 having previous treatment for DC in the same finger
being considered for the intervention
 having previous surgery or a major injury that
affects the same fingers movement
 having complex regional pain syndrome, infection,
or an allergic reaction to the CCH before
randomisation
 having a tendon or ligament rupture in the hands
before randomisation
 a patient incapable of complying with a therapy
program due to cognitive or language challenges.
Activity performance and satisfaction are affected by
capacity of both hands. Therefore, participation in the
study is appropriate only once. If any of the included
participants receive DC treatment in the unparticipating
hand, or for other fingers of the experimental hand, dur-
ing the present trial, this will be noted and considered as
an adjustment variable in the analysis. Previous injury or
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DC treatment would undoubtedly cause changes in the
connective tissue and would likely confound the results
of our study. Participants who develop complex regional
pain syndrome (CRPS) or infection, diagnosed by a doc-
tor, must undergo hand therapy regardless of whether it
affects hand function severely. This will be considered in
the analysis as an adjustment variable.
Enrolment and assessment schedule
Prospective participants are identified from the pa-
tients on the waiting list for CCH treatment at our
hospital. They are contacted by a postal letter in the
post. In the letter they are invited to participate in
the study in the same letter that informs them about
the time schedule for CCH treatment. A written, in-
formed consent form is signed by the patient before
demographic and medical information are collected,
and baseline testing is conducted, including ROM
(see below). Immediately after the CCH treatment,
ROM will be measured again. Then, participants will
be randomly assigned to receive either hand therapy
or no hand therapy. The intervention starts on the
same day of the extension procedure (see below), just
after group assignment. The first follow-up time for
all outcome measures will be set at 6 weeks post-
CCH, so that possible recurrence can be assessed at
Fig. 1 Flow chart illustrating the selection, allocation, intervention, and assessment schedule of patients with Dupuytren’s contracture. a Reasons
for receiving hand therapy after allocation to the control group are developing CRPS or an infection. This will be noted and considered in
the analysis
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1 year [39]. A second assessment time will occur at 4
months post-CCH, when the routine night-time splint
is discontinued (see below). At one-year post-CCH, a
final assessment will be done. This point was selected
to allow time for the healing process to complete and
to detect potential recurrences of DC [31, 39]. A flow
diagram for selection and assessment of participants
is shown in Fig. 1.
Randomisation and blinding
Included participants will be allocated to the four groups by
a block randomisation method, stratified for PIPJ affection
in one or more of the treated fingers, and MCPJ contrac-
tures (without PIPJ affection in any of the treated fingers).
The randomisation schedule will be prepared using soft-
ware by an independent statistician not involved in the
study. The project group will be blinded for the block size.
The assignment to either the hand therapy group or the
control group will be put in sealed opaque envelopes with
numbers, following an order generated by the software. A
list with the numbers of the envelopes will be marked when
the envelopes are used. The list and envelopes will be stored
in a private locked closet that is inaccessible to blinded
study researchers. The envelope will be opened by the par-
ticipant and a receptionist when the CCH treatment is fin-
ished. If the participant is allocated to the hand therapy
group, the therapy starts at the day of the extension proced-
ure. The surgeon is also blind to participant allocation,
since the CCH treatment is finished before allocation. It is
not possible for the therapist performing the hand therapy
intervention to be blinded, but the person performing and
managing the assessments will be blinded. The participant
will be instructed not to inform the assessor of their alloca-
tion group, nor to reveal any related aspects during any of
the assessments. By nature of PIPJ and MCPJ DCs, it is im-
possible to blind this subgroup allocation.
Intervention
All participants
Participants in the two groups are all treated with a colla-
genase injection (i.e., CCH) and extension procedure. A
needle fasciotomy is done in addition in the same proced-
ure for a few. These will be marked, and considered as an
adjustment variable in the analysis. If the extension pro-
cedure causes a wound, it is dressed, and the patient is in-
formed on how to prevent infection. An employer sick
note is provided if needed. Further intervention depends
on group assignment.
Control group
Participants in the control group are discharged from
hospital without further interventions, not even a post-
treatment appointment with the surgeon. The participants
in this group are neither informed of what exercises to do,
nor are they to be fitted for a splint or cast. If an infection
is detected or CRPS diagnosed by the personal general
practitioner or the surgeon, treatment accordingly (most
often hand therapy) will be initiated. The Budapest criteria
for CRPS will be used [40]. If not diagnosed when meeting
at the 6 weeks or 4months re-tests, the tester will contact
a MD to do it. If CRPS develops, this participant will be
marked as treated with a deviation from the protocol (Fig.
1). This marking will also be done if it is revealed that a
participant has received some kind of hand therapy out-
side of the hospital.
Intervention group
Hand therapy comprises the following. To ensure the best
possible treatment, we will give each participant an infor-
mation leaflet and a diary for them to record specific notes
about their therapy experience. The information discusses
oedema and scar management, correct night-time splint-
ing, hand exercises, and everyday activities to be done for
the entire post-CCH and follow-up periods. Participants
of the hand therapy group are instructed by an occupa-
tional therapist experienced in hand therapy for DC at the
day of the extension procedure. An extension splint is
moulded, and night-time splinting begins at this time. In-
structions on how to do hand exercises are also given.
Specifically, participants are asked to and instructed how
to perform the daily activities listed in the Canadian Occu-
pational Performance Measure (COPM). Depending on
the patient’s needs and progress of oedema, scarring,
proper splint adjustments, ROM, and mastering everyday
activities, the timing and the amount of therapy sessions
will vary individually. The participants will at least be seen
at 4 and 6 weeks, but mostly they will also be seen at 1–2
weeks post CCH-treatment. The participants will be
instructed in how to do exercises, use their hand in daily
activities as exercise and treat their scar or oedema on
their own. Use of the routine night-time splint will be
discontinued at 4 months. Some participants might
voluntarily choose to use it beyond the 4months; this is
noted. Therapy sessions might continue after 4months, as
it sometimes takes time to elongate structures surround-
ing the joints. If there is a persistent rest-contracture, this
is noted. The therapist and participant end hand-therapy
sessions when no improvement of joint extension is
achieved for two sessions with 2months apart, or if full
ROM is achieved, whichever comes first. The intervention
group is free to contact the study’s occupational therapist
at any time during the trial.
Oedema and scar management
Oedema treatment is standard, and comprises rest and
elevation of the hand in combination with movement of
the whole arm and use of the affected hand in everyday
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activities. Compression achieved with an elastic self-adhe-
sive bandage or with a oedema glove is recommended for
12 h per day for prolonged oedema (i.e., lasting more than
72 h) as long as it persists.
Every laceration leaves a scar. If present, scar treatment
is standard, comprising application of pressure through a
splint or paper tape, and sometimes includes silicone
treatment [23]. If the scar is hard or hypertrophic, use of a
splint together with a silicone sheet is recommended [26–
28]. Scar and oedema treatment is recommended for 12 h
per day for 2months or more, if needed [41].
If needed for oedema management, exercises are per-
formed as long as the oedema persists, and include the
following:
 move arms up above the head and down again
 make a fist and stretch the fingers out (Figs. 2 and 3)
 keep the arm elevated by resting it on the chest
when walking about or on a pillow for the first 2–3
days (inflammation-phase)
Splinting
The splint is an individually moulded volar splint
made of thermoplastic. It is custom-formed to ac-
commodate the treated finger(s) and the neighbour-
ing finger, with the MCPJs slightly bent and PIPJs
extended (Figs. 4 and 5). As the hand is sedated at
the time the splint is moulded, we do not know
whether wearing the splint will be painful. When the
splint is being fitted, too much pressure on the
fingers and excessive tension at the possible wound
site must be avoided. When the wound has healed
and as pain thresholds permit, the splint can be
remoulded as appropriate. Elastic Velcro is adhered
dorsally to prevent the splint from twisting and
turning, and is sufficiently wide to produce light
pressure for elongating structures, if necessary. Par-
ticipants are encouraged to contact the therapist for
splint adjustments, if something prevents them from
wearing it. Precautions will be specifically guided by
patient-reported pain, as pain is indicative of pos-
sible micro tears in hand tissues, leading to scarring
and more contractures. If the PIPJ contracture is se-
vere (≥40 degrees) post-CCH, an even more-targeted
splint for the specific joint will be constructed when
the possible wound is sufficiently healed – a finger
Gutter splint” (Figs. 6 and 7) or a three point finger
splint (Figs. 8 and 9).Fig. 2 Make a fist
Fig. 3 Stretch out the fingers Fig. 4 Night splint volar side
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Exercises
Patients are instructed to perform the exercises at
home several times a day for short sessions, complet-
ing 10 repetitions for each exercise.
Hand exercises, if hand function is impaired:
 make a fist and stretch out the fingers to engage
finger movement (Figs. 2 and 3)
 isolated exercises for the specific joint(s)
(Fig. 10, 11 and 12)
Hand exercises, if the PIPJ is involved:
 flexion of the DIPJ with the PIPJ held in extension
to lengthen the oblique retinacular ligaments
(Fig. 10)Fig. 7 Finger gutter splint, dorsal side
Fig. 8 Finger three-point splint volar side
Fig. 9 Finger three-point splint dorsal side
Fig. 5 Night splint dorsal side
Fig. 6 Finger gutter splint, volar side
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 extension of the PIPJ and DIPJ with the MCPJ
blocked in flexion (Fig. 13)
Everyday activities
The therapy sessions will focus on activities listed in
each patients’ COPM. The activities will be written
in the diary to aid the patient’s memory. The
therapist will guide the patients in how to use these
activities as exercise, and will motivate the patients
by explaining that performing rote exercises, in com-
bination with other exercises through meaningful
activities, produces better results [40].
Treatment adherence
Patients in the intervention group will receive written
instructions containing all the information about
their treatment. They will meet the therapist indi-
vidually as often as necessary, and for a minimum of
three sessions: (1) at the day of the extension
procedure; (2) within 4 weeks; and (3) at 6 weeks.
They are free to contact the therapist if needed. This
follow-up is designed to encourage treatment
adherence.
Outcome measures
Recommendations for assessing treatment progress for
DC will be used [42, 43]. These include a combin-
ation of generic patient-reported outcome measures
(PROM), a disease-specific questionnaire, a physical
measure of active and passive individual joint ROM,
and grip strength, using standardised protocols for
DC assessment. An overview of the measures used is
presented in Table 1 together with the schedule of
when they are performed. Differences in performance
parameters between the two groups will be evaluated.
Subgroups will be similarly evaluated. Patient per-
formance of and self-satisfaction with performance of
everyday activities 1 year after CCH treatment will be
the main outcome of interest.
Fig. 10 Isolated exercise for DIPJ
Fig. 12 Isolated exercise for MCPJ
Fig. 11 Isolated exercise for PIPJ
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Primary outcome measure: Canadian model of
occupational performance
The Canadian Occupational Performance Measure
(COPM) is a client-centred tool, with which individuals
identify and prioritise everyday issues that restrict or im-
pact their performance of everyday living activities [44].
The Norwegian version of the COPM will be used [45].
The COPM is reliable [46], has good construct validity
for DC [47], as well as criterion responsiveness [48]. It is
a relevant instrument for the population of DC sufferers
and captures performance problems that may be missed
by other tests [47].
This self-perception of performance and satisfaction with
performance is tracked over time by the tool. To optimise
the relevance of the COPM in this study, participants are
asked to identify activity limitations caused as a result of
their DC. Participants rate the importance of each activity
on a scale from 1 to 10, and they select a maximum of five
activity limitations that they feel are the most important ac-
tivities they want to improve. The participants evaluate each
activity with regard to their actual performance and satisfac-
tion with their performance on a scale from 1 to 10; higher
values indicate better performance or greater satisfaction.
The mean total performance score and satisfaction score
will be calculated over the chosen activities. We deemed a
change in score of 2 as a clinically important change, a value
indicated in the literature for the COPM [44].
At each of the follow-up assessments, participants will
rate their current performance and satisfaction with
their performance of each of the five activities that they
identified at baseline. Change scores are calculated using
the previous scores and the current ones.
Secondary outcomes
Unité Rhumatologique des affections de la Main (URAM)
scale
To better compare the results of this proposed trial on
DC with other studies, and to examine participants’ per-
formance of predefined disease-specific activities, we will
use the Norwegian version of the Unité Rhumatologique
des Affections de la Main (URAM-N) scale [49]. Per-
formance of nine predefined activity limitations is evalu-
ated on six different degrees of performance. With the
URAM-N, a maximum score of 45 is possible, indicating
the worst possible condition. The original version of the
URAM scale has strong convergence with the Tubiana
scale (contractures of the joints) and self-assessed dis-
ability measured with a visual analogue scale (VAS) [3].
The clinimetric properties for the Norwegian scale have
not been tested yet.
Range of motion (ROM)
In the majority of research on DC treatments, ROM
is the primary outcome variable. In the present trial,
Fig. 13 Extension of the PIPJ and DIPJ with the MCPJ blocked in flexion
Table 1 Schedule of enrolment, interventions, and assessments
of patients with Dupuytren’s contracture
Enrolment Baseline
tests
CCH
treatment
6
weeks
follow
up
4
months
follow
up
1 year
follow
up
ENROLEMENT:
Eligibility screen X
Informed consent X
Randomisation X
INTERVENTIONS:
Hand therapy X X X
No hand therapy X X X X
ASSESSMENTS:
Demographic and medical
variables
X X X X
Main outcome
Everyday activities:
COPM
X X X X
Secondary outcomes
Range of motion:
Goniometer
X X X X X
Everyday living activities:
URAM scale
X X X X
Grip force:
Jamar dynamometer
X X X X
Pain:
VAS
X X X X
Cold hypersensitivity:
Yes/no
X X X X
Sick leave:
Yes/no
X X X X
Satisfaction with change
in hand function: PGIC
X X
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group differences in mean change of ROM (active
flexion and active/passive extension of each treated
joint) will be evaluated. DC recurrence rates will also
be evaluated in the four groups. We define a success-
ful result as (1) a joint that achieves an extension to
0–5 degrees of full extension, and (2) a clinical im-
provement of more than 50% reduction of the ori-
ginal contracture [12]. We adopted recommendations
to improve ROM measuring and reporting [39, 50]. A
Rolyan goniometer with a precision of five-degree in-
tervals (range, 0–180 degrees) will be used to measure
ROM, as it is the established ROM-measuring tool
routinely used in a clinical context. Only treated
joints will be measured for ROM.
The Swedish Hand Surgical Quality National Register
(HAKIR) reached a consensus on how to measure ROM
with a goniometer [51]. This method will be followed,
and in addition, we will measure with the elbow resting
on a table, hand up, and wrist in neutral position. MCPJs
will be both flexed and then extended when measuring
PIPJ extension. Active flexion and both passive and ac-
tive extension of each treated joint will be measured sep-
arately. The results will be tabulated, as recommended
by Kan et al. [39]. Extension deficit is marked with a
minus sign, full extension and hyperextension is defined
as zero degrees. We define DC recurrence as an increase
in treated-joint contracture at the one-year follow-up of
at least 20 degrees compared to the six-weeks follow-up
measurement [39].
Following the COSMIN criteria [52], one systematic
review found a limited level of evidence for an accept-
able reliability in the dorsal measurement method of
goniometry assessment of the finger joints, and an un-
known level of evidence for the measurement error [53].
Grip force
We will evaluate group differences in mean change
scores on grip force. A calibrated Jamar dynamometer
will be used, which is a hydraulic hand-held tool cap-
able of measuring grip force from 0 to 90 kg. A peak
hold needle retains the highest reading until the de-
vice is reset. The Swedish HAKIR manual for measur-
ing grip force will be followed [51]. The measurement
shows good test-retest, inter-tester, and intra-tester
reliability [54–57].
Pain
For characteristics that can take on values spanning a con-
tinuum that cannot be easily measured directly, a reliable
proxy measure can be obtained with a VAS ranging from
0 to 10 cm. Participants are asked to indicate the intensity
of their pain symptom along a straight line measuring 10
cm. The end points of the line are labelled as the extreme
lower and upper limits of the describable pain, with 10 in-
dicating the worst possible, and 1 indicating no pain [58].
We will ask the participants how much pain they experi-
enced in the treated hand in the last 24 h before the
present assessment. The VAS which the participant is
asked to mark has only the endpoints labelled with no
numbers on it. On the backside of the VAS there will be
numbers 0-100mm, for the tester to register.
Patient global impression of change
At the four-month and one-year follow-ups, participants
will be asked how satisfied or unsatisfied they are with
the change in hand function compared to the situation
prior to CCH treatment. The Patient Global Impression
of Change (PGIC) will be used [59]. The questions for
the PGIC refer to the following statement: “My hand
function has changed since the collagenase treatment.”
“Are you satisfied with the change?” The patients are
instructed to state how satisfied or dissatisfied they are
across 7 levels of satisfaction ranging from not satisfied
at all to very satisfied [59].
Additional questions
Basic demographic information will be collected. Indica-
tions for treatment in other fingers in the same hand or
in the other hand will be recorded at baseline and re-
assessed at each follow-up. We will ask the participants
whether they are sensitive to cold and about sick leave,
both at baseline and at the follow-ups. Difficulties with
oedema and scarring will be queried at the follow-ups.
The participants in the intervention group will record in
a diary if they have a wound, scar, or swelling; whether
they used the splint and how much; and whether they
used the COPM activities as exercise. The diary will be
retrieved by a secretary at the four-month follow-up and
the data analyst will analyse these data after the final fol-
low-up at 1 year.
Data management
All data collected will be entered continuously, as they
become available, into SPSS (IBM SPSS Statistics for
Windows, Version 22.0. Released 2013. Armonk, NY:
IBM Corp) for subsequent analysis. The data will be
maintained on a secure HUH research server, secured in
a research database, with access granted only to the pri-
mary investigators. Identification codes of the partici-
pants and their group allocation will be kept apart from
the outcomes and demographics data. Published data
will be anonymised.
Statistical analysis
We determined the appropriate sample size according to
the minimal clinically important change for the COPM
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[44]. COPM gives two main outcomes; performance of
activity, and satisfaction with performance. There is
strong correlation between the two [60], and we there-
fore used both for the calculation of the sample size.
Van de Ven-Stevens reported a standard deviation (SD)
of 1.1 for performance and 0.8 for satisfaction for DC
patients assessed with the COPM [47]. For this trial, we
assumed a more conservative value, setting the SD to
2.0. For our power analysis, we conservatively assumed
we would detect an effect only in the PIPJ group, which
would produce a mean COPM difference of 1.0 between
the hand therapy and control groups. Power analysis
shows that we require 64 participants in each group to
detect this difference for a two-sided t-test, with a sig-
nificance level of p < 0.05 and power of 0.8. These pa-
rameters suggest we need 32 patients in each PIPJ and
MCPJ subgroup. This would enable us to detect a mean
difference of 2.0 (SD = 2) between PIPJ and MCPJ in the
intervention group, with a power of 0.98. Assuming 20%
loss-to-follow-up [22], we require 80 patients in the no
hand therapy group and 80 in the hand therapy group.
Descriptive statistics will be used to characterise the
participants’ data at baseline and follow-ups, and sep-
arately for the data of those participants who might
drop out from the study. The baseline values of every
measure will also be used to describe the randomised
groups to determine their comparability.
The effect of post-CCH hand therapy at 1 year will
be assessed using analysis of covariance (ANCOVA).
The development of changes over time will be evalu-
ated using a linear mixed-effects model, with time,
intervention group, and their interaction as predictors.
An intention-to-treat analysis will be used. The pre-
dictive value of PIPJ/MCPJ will be assessed by adding
the interaction between group and PIPJ/MCPJ to the
models. Results will be summarised by graphical
illustrations.
The significance level is set to p < 0.05. SPSS and
Matlab® (MATLAB and Statistics Toolbox Release
2012b, The MathWorks, Inc., Natick, MA, USA) will be
used for statistical analyses and creation of Figures.
Discussion of methodological limitations and
strengths
All clinical trials require completely transparent pro-
tocols [61]. By using the SPIRIT recommendations for
minimum relevant protocol items, we achieved this
goal of transparency. This paper describes the study
design for an RCT investigating the effects of hand
therapy, or lack of it, on patients who have under-
gone CCH treatment for DC. The study is also de-
signed to determine whether differences exist in the
outcome measures of patients with DC of the PIPJ in-
volved or of only the MCPJ. The design is not
optimal, as patients and therapists cannot be blinded
to the treatment modality. This is a common problem
in clinical studies. However, the therapist assessing
the participants’ performance and satisfaction, the
surgeon, and the data analyst will be blinded to the
treatment modality.
In drafting our research plan, we considered rec-
ommendations in the empirical literature on DC. It
is impossible to fully control some factors or issues.
For example, the presentation of DC varies consider-
ably, making each DC case unique. Thus, patients
will respond differently to the CCH treatment and
will thus require different therapeutic interventions
to address their unique complaints. Also, as DC is a
chronic disorder, the disease itself remains active
even after treatment and thus contractures may con-
tinue to occur. Another issue that we cannot control
is the structural status or integrity of tissues sur-
rounding the affected joint. Those structures may be
so stiff that it would be impossible to fully straighten
the affected joint. These issues make research on DC
treatments and rehabilitation challenging. Our study,
however, has attempted to control for some of these
variations by incorporating two subgroups, one com-
prising patients with PIPJ contractures and the other
comprising patients with only MCPJ contractures.
We surmise that one of the subgroup of patients
may require more intensive hand therapy than the
other.
A potential source of limitations is our choice of out-
come measures. One of these measures is the URAM
scale, a disease-specific self-assessment scale that mea-
sures disability due to DC [20]. The URAM scale has
been criticised for not embracing all of the most import-
ant activity limitations of DC patients [20]. Thus, its face
validity might need to be reassessed and perhaps modi-
fied. Another tool we use in this RCT is COPM, a tool
that identifies occupational activities patients have diffi-
culty performing [47]. The COPM may reveal important
activity limitations not identified by other patient-related
outcome measures [47], as it can be used to gather in-
formation about the most important activities patients
perform in daily life. COPM will enable us to determine
and gauge the patients’ satisfaction with their activity
performance. This may give healthcare professionals
wider insight into the patients’ activity limitations after
CCH treatment. One reason it may not appear to assess
certain activity limitations is that our experience shows
that patients may actually experience disease-related
problems, but they do not recognise them as such and
thus do not note them accordingly on the COPM. Using
two complementary assessment scales-COPM and
URAM, ensures that all activities salient to DC patients
are assessed.
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One possible limitation with the study relates to DC no-
menclature and terminology. Studying contracture recur-
rence and comparing recurrent rates from the literature is
a challenge, since these terms were not uniformly defined
until 2017 [39]. Different definitions for recurrence greatly
influence the reported recurrence rates. In addition, ROM
lacks clarity in earlier research and there are different
methods for measuring it [50, 53]. In the context of a con-
sensus definition of DC recurrence, it is recommended to
measure each joint separately [39]. HAKIR describes a
consensus protocol on how to measure the ROM [51].
There are other various factors that can affect our
study outcomes, such as to what extent patients perform
daily activities and whether they employ other strategies
to improve their hand function. To date, no studies have
been published that examined how performing daily ac-
tivities can improve hand function in DC patients. In the
present study, the hand therapy group will be encour-
aged by the occupational therapist to engage in daily ac-
tivities. The therapist will demonstrate how these
activities can be used to improve their hand mobility
and function, and discuss its benefits. The control group
will also be using their hands for daily activities and they
may improve. We will determine whether this type of in-
struction will improve the performance of everyday ac-
tivities compared to if not, wherein patients do not
undergo hand therapy and thus do not receive specific
instructions on exercising their hand as they perform
daily activities. Through regular study follow-ups, the no
hand therapy group will become aware of what functions
we expect to improve. If the control patients did not
participate in our study, they would be unaware of what
functions to improve, and thus might not try to improve
them. We cannot control what the patients do to im-
prove their hand function on their own.
The hypotheses are about the patient performance
and satisfaction with performance of everyday activ-
ities, and about the anticipation that the joint involve-
ment has an impact. The study will look at therapy
as a whole package; it will not be possible to tell
which part of the therapy is beneficial or not. The
question if a splint is needed will not be answered,
and have to be investigated in a later study if therapy
show beneficial effect.
Research on DC and its treatment is challenging,
both in regard to the kind of medical approach used
and to the kind of therapy selected after treatment.
Our goal in this study is to produce empirically de-
fined recommendations for therapy following CCH
treatment, taking into consideration that each patient
is unique, and that recurrence can occur because the
disease is not curable. The intervention will differ
slightly according to the patients’ symptoms, reflecting
standard clinical practice. The study will objectively
answer the question of whether or not hand therapy
makes a difference on activity performance and pa-
tient self-satisfaction with performance, and whether
the particular joints involved (i.e., PIPJ or MCPJ) dif-
fer with respect to performance and self-satisfaction
outcomes. These results will provide an objective
basis to inform policies of referral for hand therapy
after CCH treatment.
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